Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on a late-stage study for its bispecific antibody (BsAb) Rybrevant (amivantamab). The study investigated the combination of Rybrevant with tyrosine kinase inhibitor (TKI) lazertinib and chemotherapy in treating advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletions or L858R substitution after disease progression.
Primary Endpoint Achievement and Safety Profile
According to Janssen, the trial successfully met its primary endpoint, demonstrating an improvement in progression-free survival (PFS) for patients. Additionally, the study did not identify any new safety signals for the first-in-class anti-EGFR-MET BsAb, Rybrevant. These results are encouraging for the potential use of this treatment combination in the fight against NSCLC.
Developing Rybrevant as a First-Line Treatment
The combination therapy of Rybrevant and lazertinib is also under development for use as a first-line treatment for EGFR-mutated NSCLC. This development pipeline indicates Janssen’s commitment to exploring the full potential of Rybrevant in addressing the complex needs of NSCLC patients.-Fineline Info & Tech
